mesna
General
Pronunciation:
mes-na
Trade Name(s)
- Mesnex
- Uromitexan
Ther. Class.
antidotes
Pharm. Class.
ifosfamide detoxifying agents
Indications
Prevention of ifosfamide-induced hemorrhagic cystitis.
Unlabeled Use(s):
Prevention of cyclophosphamide-induced hemorrhagic cystitis.
Action
Binds to the toxic metabolites of ifosfamide in the kidneys.
Therapeutic Effect(s):
Prevents hemorrhagic cystitis from ifosfamide.
Pharmacokinetics
Absorption: IV administration results in complete bioavailability; 45–79% absorbed after oral administration. Following IV with PO dosing ↑ systemic exposure.
Distribution: Minimally distributed to tissues.
Metabolism and Excretion: Rapidly converted to mesna disulfide, then back to mesna in the kidneys, where it binds to toxic metabolites of ifosfamide (18–26% excreted as free mesna in urine after IV and PO dosing).
Half-life: Mesna: 0.36 hr (IV); 1.2–8.3 hr (IV followed by PO); Mesna disulfide: 1.17 hr.
TIME/ACTION PROFILE (detoxifying action)
ROUTE | ONSET | PEAK | DURATION |
---|---|---|---|
PO, IV | rapid | unknown | 4 hr |
Contraindication/Precautions
Contraindicated in:
- Hypersensitivity to mesna or other thiol (rubber) compounds;
- Lactation: Lactation.
Use Cautiously in:
- OB: Safety not established in pregnancy;
- Pedi: Injection contains benzyl alcohol, which can cause potentially fatal "gasping syndrome" in neonates.
Adverse Reactions/Side Effects
Derm: flushing
GI: anorexia, diarrhea, nausea, unpleasant taste, vomiting
Local: injection site reactions
Neuro: dizziness, drowsiness, headache
Misc: flu-like symptoms
* CAPITALS indicate life-threatening.
Underline indicate most frequent.
Interactions
Drug-Drug
None reported.
Route/Dosage
IV (Adults): Give a dose of mesna equal to 20% of the ifosfamide dose at the same time as ifosfamide and 4 and 8 hr after.
PO IV (Adults): Give a dose of IV mesna equal to 20% of the ifosfamide dose at the same time as ifosfamide; then give PO mesna equal to 40% of the ifosfamide dose 2 and 6 hr after ifosfamide (total mesna dose is 100% of ifosfamide dose).
Availability (generic available)
Solution for injection: 100 mg/mL
Tablets: 400 mg
Assessment
- Monitor for development of hemorrhagic cystitis in patients receiving ifosfamide.
Lab Test Considerations:
Obtain a negative pregnancy test before starting when mesna is given with ifosfamide.
Causes a false-positive result when testing urinary ketones.Implementation
- Initial IV bolus is to be given at time of ifosfamide administration.
- PO If second and third doses are given orally, administer 2 and 6 hr after IV dose.
- If PO mesna is vomited within 2 hr of administration, repeat dose or use IV mesna.
Syringe Compatibility
- ifosfamide
- Y-Site Compatibility:
- alemtuzumab
- allopurinol
- amifostine
- MORE...
- amikacin
- aminocaproic acid
- aminophylline
- amiodarone
- amphotericin B liposomal
- ampicillin
- ampicillin/sulbactam
- anidulafungin
- argatroban
- azithromycin
- aztreonam
- bivalirudin
- bleomycin
- bumetanide
- buprenorphine
- butorphanol
- calcium acetate
- calcium chloride
- calcium gluconate
- carmustine
- caspofungin
- cefazolin
- cefepime
- cefotaxime
- cefotetan
- cefoxitin
- ceftriaxone
- cefuroxime
- chloramphenicol
- chlorpromazine
- ciprofloxacin
- cisatracurium
- cladribine
- clindamycin
- cyclophosphamide
- cytarabine
- dactinomycin
- dexamethasone
- dexmedetomidine
- dexrazoxane
- digoxin
- diltiazem
- diphenhydramine
- dobutamine
- docetaxel
- dopamine
- doxorubicin hydrochloride
- doxorubicin liposomal
- doxycycline
- droperidol
- enalaprilat
- ephedrine
- epinephrine
- epirubicin
- ertapenem
- erythromycin
- esmolol
- etoposide
- etoposide phosphate
- famotidine
- fentanyl
- filgrastim
- fluconazole
- fludarabine
- fluorouracil
- foscarnet
- fosphenytoin
- furosemide
- gemcitabine
- gentamicin
- glycopyrrolate
- granisetron
- haloperidol
- heparin
- hetastarch
- hydralazine
- hydrocortisone
- hydromorphone
- idarubicin
- ifosfamide
- imipenem/cilastatin
- insulin, regular
- irinotecan
- isoproterenol
- ketorolac
- labetalol
- leucovorin
- levofloxacin
- lidocaine
- linezolid
- lorazepam
- magnesium sulfate
- mannitol
- melphalan
- meperidine
- meropenem
- methotrexate
- methylprednisolone
- metoclopramide
- metoprolol
- metronidazole
- micafungin
- midazolam
- milrinone
- mitomycin
- mitoxantrone
- morphine
- moxifloxacin
- mycophenolate
- nafcillin
- nalbuphine
- naloxone
- nitroglycerin
- norepinephrine
- octreotide
- ondansetron
- oxaliplatin
- paclitaxel
- palonosetron
- pamidronate
- pantoprazole
- pemetrexed
- pentamidine
- pentobarbital
- phenobarbital
- phenylephrine
- piperacillin/tazobactam
- potassium acetate
- potassium chloride
- potassium phosphate
- procainamide
- prochlorperazine
- promethazine
- propranolol
- remifentanil
- rituximab
- rocuronium
- sargramostim
- sodium acetate
- sodium bicarbonate
- sodium phosphate
- succinylcholine
- sufentanil
- tacrolimus
- theophylline
- thiotepa
- tigecycline
- tirofiban
- tobramycin
- topotecan
- trastuzumab
- vancomycin
- vasopressin
- vecuronium
- verapamil
- vinblastine
- vincristine
- vinorelbine
- voriconazole
- zidovudine
- zoledronic acid
- Y-Site Incompatibility:
- acyclovir
- amphotericin B deoxycholate
- amphotericin B lipid complex
- MORE...
- dacarbazine
- dantrolene
- diazepam
- ganciclovir
- nicardipine
- nitroprusside
- phenytoin
- thiopental
- Rate: Administer over 15–30 min or as a continuous infusion.
Syringe Compatibility
- ifosfamide
- Y-Site Compatibility:
- alemtuzumab
- allopurinol
- amifostine
- MORE...
- amikacin
- aminocaproic acid
- aminophylline
- amiodarone
- amphotericin B liposomal
- ampicillin
- ampicillin/sulbactam
- anidulafungin
- argatroban
- azithromycin
- aztreonam
- bivalirudin
- bleomycin
- bumetanide
- buprenorphine
- butorphanol
- calcium acetate
- calcium chloride
- calcium gluconate
- carmustine
- caspofungin
- cefazolin
- cefepime
- cefotaxime
- cefotetan
- cefoxitin
- ceftriaxone
- cefuroxime
- chloramphenicol
- chlorpromazine
- ciprofloxacin
- cisatracurium
- cladribine
- clindamycin
- cyclophosphamide
- cytarabine
- dactinomycin
- dexamethasone
- dexmedetomidine
- dexrazoxane
- digoxin
- diltiazem
- diphenhydramine
- dobutamine
- docetaxel
- dopamine
- doxorubicin hydrochloride
- doxorubicin liposomal
- doxycycline
- droperidol
- enalaprilat
- ephedrine
- epinephrine
- epirubicin
- ertapenem
- erythromycin
- esmolol
- etoposide
- etoposide phosphate
- famotidine
- fentanyl
- filgrastim
- fluconazole
- fludarabine
- fluorouracil
- foscarnet
- fosphenytoin
- furosemide
- gemcitabine
- gentamicin
- glycopyrrolate
- granisetron
- haloperidol
- heparin
- hetastarch
- hydralazine
- hydrocortisone
- hydromorphone
- idarubicin
- ifosfamide
- imipenem/cilastatin
- insulin, regular
- irinotecan
- isoproterenol
- ketorolac
- labetalol
- leucovorin
- levofloxacin
- lidocaine
- linezolid
- lorazepam
- magnesium sulfate
- mannitol
- melphalan
- meperidine
- meropenem
- methotrexate
- methylprednisolone
- metoclopramide
- metoprolol
- metronidazole
- micafungin
- midazolam
- milrinone
- mitomycin
- mitoxantrone
- morphine
- moxifloxacin
- mycophenolate
- nafcillin
- nalbuphine
- naloxone
- nitroglycerin
- norepinephrine
- octreotide
- ondansetron
- oxaliplatin
- paclitaxel
- palonosetron
- pamidronate
- pantoprazole
- pemetrexed
- pentamidine
- pentobarbital
- phenobarbital
- phenylephrine
- piperacillin/tazobactam
- potassium acetate
- potassium chloride
- potassium phosphate
- procainamide
- prochlorperazine
- promethazine
- propranolol
- remifentanil
- rituximab
- rocuronium
- sargramostim
- sodium acetate
- sodium bicarbonate
- sodium phosphate
- succinylcholine
- sufentanil
- tacrolimus
- theophylline
- thiotepa
- tigecycline
- tirofiban
- tobramycin
- topotecan
- trastuzumab
- vancomycin
- vasopressin
- vecuronium
- verapamil
- vinblastine
- vincristine
- vinorelbine
- voriconazole
- zidovudine
- zoledronic acid
- Y-Site Incompatibility:
- acyclovir
- amphotericin B deoxycholate
- amphotericin B lipid complex
- MORE...
- dacarbazine
- dantrolene
- diazepam
- ganciclovir
- nicardipine
- nitroprusside
- phenytoin
- thiopental
IV Administration
Intermittent Infusion: 2nd IV dose is given 4 hr later, 3rd dose is given 8 hr after initial dose. This schedule must be repeated with each subsequent dose of ifosfamide. Dilution: Dilute 2-, 4-, and 10-mL ampules, containing a concentration of 100 mg/mL in 8 mL, 16 mL, or 50 mL, respectively, of D5W, 0.9% NaCl, D5/0.9% NaCl, D5/0.2% NaCl, D5/0.33% NaCl, or LR. Concentration: 20 mg/mL. Refrigerate to store. Use within 6 hr. Discard unused solution.
Patient/Family Teaching
- Inform patient that unpleasant taste may occur during administration.
- Advise patient to notify health care professional if nausea, vomiting, or diarrhea persists or is severe.
- Rep: Advise female patients of reproductive potential to use effective contraception during mesna/ifosfamide treatment and for 6 mo after last dose of mesna/ifosfamide and to avoid breastfeeding during mesna/ifosfamide treatment and for 1 wk after last dose of mesna/ifosfamide. Advise males with female partners of reproductive potential to use effective contraception during mesna/ifosfamide treatment and for 3 mo after last dose of mesna/ifosfamide. Advise patient to notify health care professional immediately if pregnancy is suspected.
Evaluation/Desired Outcomes
Prevention of hemorrhagic cystitis associated with ifosfamide therapy.
mesnais the Davis's Drug Guide Word of the day!